Stifel Nicolaus Has Lowered Expectations for Vor Biopharma (NYSE:VOR) Stock Price

Vor Biopharma (NYSE:VOR) had its price target lowered by equities researchers at Stifel Nicolaus from $12.00 to $5.00 in a report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 474.71% from the stock’s previous close.

Several other research firms have also issued reports on VOR. JMP Securities reiterated a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a research note on Tuesday, December 10th. Wedbush restated an “outperform” rating and set a $7.00 price target on shares of Vor Biopharma in a research note on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vor Biopharma has a consensus rating of “Buy” and a consensus price target of $8.86.

Vor Biopharma Price Performance

VOR opened at $0.87 on Friday. The business’s 50-day moving average is $1.22 and its two-hundred day moving average is $1.01. Vor Biopharma has a 1 year low of $0.63 and a 1 year high of $2.43. The firm has a market capitalization of $59.75 million, a PE ratio of -0.53 and a beta of -0.40.

Institutional Investors Weigh In On Vor Biopharma

A number of large investors have recently modified their holdings of the business. RA Capital Management L.P. lifted its holdings in shares of Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock worth $44,007,000 after purchasing an additional 16,897,159 shares during the period. Lynx1 Capital Management LP acquired a new stake in shares of Vor Biopharma during the fourth quarter worth about $707,000. Two Sigma Investments LP lifted its holdings in shares of Vor Biopharma by 18.9% during the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock worth $181,000 after purchasing an additional 25,930 shares during the period. Northern Trust Corp lifted its holdings in shares of Vor Biopharma by 39.0% during the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after purchasing an additional 44,252 shares during the period. Finally, Trustees of Columbia University in the City of New York acquired a new stake in shares of Vor Biopharma during the fourth quarter worth about $102,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.